Methodological issues in primary prevention trials for neurodegenerative dementia

Journal of Alzheimer's Disease

Volumn 16, Issue 2, 2009, Pages 235-270

  Andrieu, Sandrine ^a,b   Coley, Nicola ^a   Aisen, Paul ^c   Carrillo, Maria C ^d   Dekosky, Steven ^e   Durga, Jane ^f,u   Fillit, Howard ^g   Frisoni, Giovanni B ^h   Froelich, Lutz ⁱ   Gauthier, Serge ^j   Jones, Roy ^k   Jönsson, Linus ^l   Khachaturian, Zaven ^m   Morris, John C ⁿ   Orgogozo, Jean Marc ^o   Ousset, Pierre Jean ^b   Robert, Philippe ^p   Salmon, Eric ^q   Sampaio, Cristina ^r   Verhey, Frans ^s   Wilcock, Gordon ^t   Vellas, Bruno ^a,b   more..

^a INSERM   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c GEORGETOWN UNIVERSITY   (United States)

^d ALZHEIMER'S ASSOCIATION   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f WAGENINGEN UNIVERSITY   (Netherlands)

^g Alzheimers Drug Discovery Foundation   (United States)

^h IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

ⁱ CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^j MCGILL UNIVERSITY   (Canada)

^k Research Institute for the Care of Older People (RICE)   (United Kingdom)

^l European Health Economics   (Sweden)

^m Keep Memory Alive   (United States)

ⁿ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o HÔPITAL PELLEGRIN   (France)

^p UNIVERSITY HOSPITAL OF NICE   (France)

^q UNIVERSITY OF LIÈGE   (Belgium)

^r INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^s MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^t UNIVERSITY OF OXFORD   (United Kingdom)

^u TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

more..

Author keywords

Alzheimer's disease; Clinical trials; Clinical trials methodology; Cognitive aging; Cognitive decline; Dementia; Prevention trials; Study design

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ATENOLOL; CALCIUM; CANDESARTAN; CELECOXIB; CONJUGATED ESTROGEN; CYANOCOBALAMIN; DOCOSAHEXAENOIC ACID; ENALAPRIL MALEATE; ESTRADIOL; ESTROGEN; FOLIC ACID; GESTAGEN; GINKGO BILOBA EXTRACT; HYDROCHLOROTHIAZIDE; ICOSAPENTAENOIC ACID; INDAPAMIDE; ISOFLAVONE; MEDROXYPROGESTERONE ACETATE; MULTIVITAMIN; NAPROXEN; NITRENDIPINE; PERINDOPRIL; PYRIDOXINE; RALOXIFENE; RIBOFLAVIN; SELENIUM; UNINDEXED DRUG; VITAMIN D;

AEROBIC EXERCISE; ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DEMENTIA; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; MEMORY; OUTCOME ASSESSMENT; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; YOGA;

EID: 60349128705     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2009-0971     Document Type: Review

References (166)

1. Aguero-Torres H, Fratiglioni L, Guo Z, Viitanen M, von Strauss E, Winblad B (1998) Dementia is the major cause of functional dependence in the elderly: 3-year follow-up data from a population-based study. Am J Public Health 88, 1452-1456.
2. Ganguli M, Dodge HH, Shen C, Pandav RS, DeKosky ST (2005) Alzheimer disease and mortality: a 15-year epidemiological study. Arch Neurol 62, 779-784.
3. Jagger C, Andersen K, Breteler MM, Copeland JR, Helmer C, Baldereschi M, Fratiglioni L, Lobo A, Soininen H, Hofman A, Launer LJ (2000) Prognosis with dementia in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54, S16-20.
4. Brookmeyer R, Johnson, Ziegler G, Arrighi (2007) Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3, 186-191.
5. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112-2117.
6. Murray CJ, Lopez AD (1997) Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349, 1498-1504.
7. Jonsson L, Eriksdotter Jonhagen M, Kilander L, Soininen H, Hallikainen M, Waldemar G, Nygaard H, Andreasen N, Winblad B, Wimo A (2006) Determinants of costs of care for patients with Alzheimer's disease. Int J Geriatr Psychiatry 21, 449-459.
8. Lopez-Bastida J, Serrano-Aguilar P, Perestelo-Perez L, Oliva-Moreno J (2006) Social-economic costs and quality of life of Alzheimer disease in the Canary Islands, Spain. Neurology 67, 2186-2191.
9. Zhu CW, Scarmeas N, Torgan R, Albert M, Brandt J, Blacker D, Sano M, Stern Y (2006) Clinical characteristics and longitudinal changes of informal cost of Alzheimer's disease in the community. J Am Geriatr Soc 54, 1596-1602.
10. Zhu CW, Scarmeas N, Torgan R, Albert M, Brandt J, Blacker D, Sano M, Stern Y (2006) Longitudinal study of effects of patient characteristics on direct costs in Alzheimer disease. Neurology 67, 998-1005.
11. Alzheimer's Society (2007) Dementia UK. A report to the Alzheimer's Society on the prevalence and economic costs of dementia produced by King's College London and London School of Economics.
12. Rice DP, Fillit HM, Max W, Knopman DS, Lloyd JR, Duttagupta S (2001) Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective. Am J Manag Care 7, 809-818.
13. Brookmeyer R, Gray S, Kawas C (1998) Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 88, 1337-1342.
14. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278, 1349-1356.
15. Green RC, Cupples LA, Go R, Benke KS, Edeki T, Griffith PA, Williams M, Hipps Y, Graff-Radford N, Bachman D, Farrer LA (2002) Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA 287, 329-336.
16. Lautenschlager NT, Cupples LA, Rao VS, Auerbach SA, Becker R, Burke J, Chui H, Duara R, Foley EJ, Glatt SL, Green RC, Jones R, Karlinsky H, Kukull WA, Kurz A, Larson EB, Martelli K, Sadovnick AD, Volicer L, Waring SC, Growdon JH, Farrer LA (1996) Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: What is in store for the oldest old? Neurology 46, 641-650.
17. Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kareholt I, Winblad B, Helkala EL, Tuomilehto J, Soininen H, Nissinen A (2005) Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 62, 1556-1560.
18. Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J (2006) Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol 5, 735-741.
19. Kokmen E, Whisnant JP, O'Fallon WM, Chu CP, Beard CM (1996) Dementia after ischemic stroke: a population-based study in Rochester, Minnesota (1960-1984). Neurology 46, 154-159.
20. Peila R, White LR, Petrovich H, Masaki K, Ross GW, Havlik RJ, Launer LJ (2001) Joint effect of the APOE gene and midlife systolic blood pressure on late-life cognitive impairment: the Honolulu-Asia aging study. Stroke 32, 2882-2889.
21. Gillette Guyonnet S, Abellan Van Kan G, Andrieu S, Barberger Gateau P, Berr C, Bonnefoy M, Dartigues JF, de Groot L, Ferry M, Galan P, Hercberg S, Jeandel C, Morris MC, Nourhashemi F, Payette H, Poulain JP, Portet F, Roussel AM, Ritz P, Rolland Y, Vellas B (2007) IANA task force on nutrition and cognitive decline with aging. J Nutr Health Aging 11, 132-152.
22. Helmer C, Damon D, Letenneur L, Fabrigoule C, Barberger-Gateau P, Lafont S, Fuhrer R, Antonucci T, Commenges D, Orgogozo JM, Dartigues JF (1999) Marital status and risk of Alzheimer's disease: a French population-based cohort study. Neurology 53, 1953-1958.
23. Weih M, Wiltfang J, Kornhuber J (2007) Non-pharmacologic prevention of Alzheimer's disease: nutritional and life-style risk factors. J Neural Transm 114, 1187-1197
24. Black SE, Patterson C, Feightner J (2001) Preventing dementia. Can J Neurol Sci 28 Suppl 1, S56-66.
25. Doraiswamy PM, Xiong GL (2006) Pharmacological strategies for the prevention of Alzheimer's disease. Expert Opin Pharmacother 7, 1-10.
26. Sano M (2003) Current concepts in the prevention of Alzheimer's disease. CNS Spectr 8, 846-853.
27. Malouf R, Areosa Sastre A (2003) Vitamin B12 for cognition. Cochrane Database Syst Rev, CD004326.
28. Heyn P, Abreu BC, Ottenbacher KJ (2004) The effects of exercise training on elderly persons with cognitive impairment and dementia: a meta-analysis. Arch Phys Med Rehabil 85, 1694-1704.
29. Eussen SJ, de Groot LC, Joosten LW, Bloo RJ, Clarke R, Ueland PM, Schneede J, Blom HJ, Hoefnagels WH, van Staveren WA (2006) Effect of oral vitamin B-12 with or without folic acid on cognitive function in older people with mild vitamin B-12 deficiency: a randomized, placebo-controlled trial. Am J Clin Nutr 84, 361-370.
30. Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ (2005) Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 293, 43-53.
31. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B (2001) Current concepts in mild cognitive impairment. Arch Neurol 58, 1985-1992.
32. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC (2004) Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256, 240-246.
33. Vellas B, Andrieu S, Ousset PJ, Ouzid M, Mathiex-Fortunet H (2006) The GuidAge study: methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761 for prevention of Alzheimer disease in patients over 70 with a memory complaint. Neurology 67, S6-11.
34. DeKosky ST, Fitzpatrick A, Ives DG, Saxton J, Williamson J, Lopez OL, Burke G, Fried L, Kuller LH, Robbins J, Tracy R, Woolard N, Dunn L, Kronmal R, Nahin R, Furberg C (2006) The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. Contemp Clin Trials 27, 238-253.
35. Kryscio RJ, Mendiondo MS, Schmitt FA, Markesbery WR (2004) Designing a large prevention trial: statistical issues. Stat Med 23, 285-296.
36. Adapt Research Group, Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, Piantadosi S, Sabbagh M (2007) Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 68, 1800-1808.
37. Shumaker SA, Reboussin BA, Espeland MA, Rapp SR, McBee WL, Dailey M, Bowen D, Terrell T, Jones BN (1998) The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Control Clin Trials 19, 604-621.
38. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN, 3rd, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J (2003) Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289, 2651-2662.
39. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH (2004) Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291, 2947-2958.
40. National-Institute-on-Aging Preventing Postmenopausal Memory Loss (PREPARE). http://www.clinicaltrials.gov/ct2/show/NCT00000176?term= NCT00000176&rank=1.
41. Wolters M, Hickstein M, Flintermann A, Tewes U, Hahn A (2005) Cognitive performance in relation to vitamin status in healthy elderly German women-the effect of 6-month multivitamin supplementation. Prev Med 41, 253-259.
42. Bryan J, Calvaresi E, Hughes D (2002) Short-term folate, vitamin B-12 or vitamin B-6 supplementation slightly affects memory performance but not mood in women of various ages. J Nutr 132, 1345-1356.
43. Kang JH, Cook N, Manson J, Buring JE, Grodstein F (2006) A randomized trial of vitamin E supplementation and cognitive function in women. Arch Intern Med 166, 2462-2468.
44. Kang JH, Cook N, Manson J, Buring JE, Grodstein F (2007) Low dose aspirin and cognitive function in the women's health study cognitive cohort. BMJ 334, 987.
45. McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI, Williams SM (2006) A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med 354, 2764-2772.
46. Dangour AD, Clemens F, Elbourne D, Fasey N, Fletcher AE, Hardy P, Holder GE, Huppert FA, Knight R, Letley L, Richards M, Truesdale A, Vickers M, Uauy R (2006) A randomised controlled trial investigating the effect of n-3 long-chain polyunsaturated fatty acid supplementation on cognitive and retinal function in cognitively healthy older people: the Older People And n-3 Long-chain polyunsaturated fatty acids (OPAL) study protocol [ISRCTN72331636]. Nutr J 5, 20.
47. Almeida OP, Lautenschlager NT, Vasikaran S, Leedman P, Gelavis A, Flicker L (2006) A 20-week randomized controlled trial of estradiol replacement therapy for women aged 70 years and older: effect on mood, cognition and quality of life. Neurobiol Aging 27, 141-149.
48. Polo-Kantola P, Portin R, Polo O, Helenius H, Irjala K, Erkkola R (1998) The effect of short-term estrogen replacement therapy on cognition: a randomized, double-blind, cross-over trial in postmenopausal women. Obstet Gynecol 91, 459-466.
49. Binder EF, Schechtman KB, Birge SJ, Williams DB, Kohrt WM (2001) Effects of hormone replacement therapy on cognitive performance in elderly women. Maturitas 38, 137-146.
50. Mahncke HW, Connor BB, Appelman J, Ahsanuddin ON, Hardy JL, Wood RA, Joyce NM, Boniske T, Atkins SM, Merzenich MM (2006) Memory enhancement in healthy older adults using a brain plasticity-based training program: a randomized, controlled study. Proc Natl Acad Sci U S A 103, 12523-12528.
51. Oken BS, Zajdel D, Kishiyama S, Flegal K, Dehen C, Haas M, Kraemer DF, Lawrence J, Leyva J (2006) Randomized, controlled, six-month trial of yoga in healthy seniors: effects on cognition and quality of life. Altern Ther Health Med 12, 40-47.
52. Jobe JB, Smith DM, Ball K, Tennstedt SL, Marsiske M, Willis SL, Rebok GW, Morris JN, Helmers KF, Leveck MD, Kleinman K (2001) Active: A cognitive intervention trial to promote independence in older adults. Controlled Clinical Trials 22, 453-479.
53. Willis SL, Tennstedt SL, Marsiske M, Ball K, Elias J, Koepke KM, Morris JN, Rebok GW, Unverzagt FW, Stoddard AM, Wright E (2006) Long-term effects of cognitive training on everyday functional outcomes in older adults. JAMA 296, 2805-2814.
54. Stott DJ, MacIntosh G, Lowe GD, Rumley A, McMahon AD, Langhorne P, Tait RC, O'Reilly DS, Spilg EG, MacDonald JB, MacFarlane PW, Westendorp RG (2005) Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease. Am J Clin Nutr 82, 1320-1326.
55. Lewerin C, Matousek M, Steen G, Johansson B, Steen B, Nilsson-Ehle H (2005) Significant correlations of plasma homocysteine and serum methylmalonic acid with movement and cognitive performance in elderly subjects but no improvement from short-term vitamin therapy: a placebo-controlled randomized study. Am J Clin Nutr 81, 1155-1162.
56. Dodge HH, Zitzelberger T, Oken BS, Howieson D, Kaye J (2008) A randomized placebo-controlled trial of ginkgo biloba for the prevention of cognitive decline. Neurology 70, 1809-1817.
57. Ho SC, Chan AS, Ho YP, So EK, Sham A, Zee B, Woo JL (2007) Effects of soy isoflavone supplementation on cognitive function in Chinese postmenopausal women: a doubleblind, randomized, controlled trial. Menopause 14, 489-499.
58. Durga J, van Boxtel MP, Schouten EG, Kok FJ, Jolles J, Katan MB, Verhoef P (2007) Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet 369, 208-216.
59. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI (2005) Estrogen therapy and risk of cognitive decline: results from the Women's Estrogen for Stroke Trial (WEST). Am J Obstet Gynecol 192, 387-393.
60. Yaffe K, Krueger K, Cummings SR, Blackwell T, Henderson VW, Sarkar S, Ensrud K, Grady D (2005) Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry 162, 683-690.
61. Yaffe K, Krueger K, Sarkar S, Grady D, Barrett-Connor E, Cox DA, Nickelsen T (2001) Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 344, 1207-1213.
62. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, Chalmers J (2003) Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 163, 1069-1075.
63. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, Kobalava Z, Sarti C, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Birkenhager WH (2002) The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 162, 2046-2052.
64. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T, Lilov E, Moisseyev V, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Fagard R (1998) Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352, 1347-1351.
65. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A (2003) The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21, 875-886.
66. Prince MJ, Bird AS, Blizard RA, Mann AH (1996) Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. BMJ 312, 801-805.
67. Applegate WB, Pressel S, Wittes J, Luhr J, Shekelle RB, Camel GH, Greenlick MR, Hadley E, Moye L, Perry HM, Jr., et al. (1994) Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch Intern Med 154, 2154-2160.
68. McNeill G, Avenell A, Campbell MK, Cook JA, Hannaford PC, Kilonzo MM, Milne AC, Ramsay CR, Seymour DG, Stephen AI, Vale LD (2007) Effect of multivitamin and multimineral supplementation on cognitive function in men and women aged 65 years and over: a randomised controlled trial. Nutr J 6, 10.
69. Peters R, Beckett N, Nunes M, Fletcher A, Forette F, Bulpitt C (2006) A substudy protocol of the hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG) : An ongoing randomised, doubleblind, placebo-controlled trial. Drugs Aging 23, 83-92.
70. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M (2004) Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291, 565-575.
71. Prince M. A randomised placebo-controlled trial of the effect of hormone replacement therapy on dementia and cognitive function in post-menopausal women. http://www.controlledtrials.com/ISRCTN55999335/ISRCTN55999335.
72. Vickers MR, Martin J, Meade TW (2007) The Women's international study of long-duration oestrogen after menopause (WISDOM): a randomised controlled trial. BMC Womens Health 7, 2.
73. Williamson JD, Miller ME, Bryan RN, Lazar RM, Coker LH, Johnson J, Cukierman T, Horowitz KR, Murray A, Launer LJ (2007) The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. Am J Cardiol 99, 112i-122i.
74. Yaffe K, Clemons TE, McBee WL, Lindblad AS (2004) Impact of antioxidants, zinc, and copper on cognition in the elderly: a randomized, controlled trial. Neurology 63, 1705-1707.
75. Grady D, Yaffe K, Kristof M, Lin F, Richards C, Barrett-Connor E (2002) Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study. Am J Med 113, 543-548.
76. (2002) MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 23-33.
77. (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22.
78. Grodstein F, Kang JH, Glynn RJ, Cook NR, Gaziano JM (2007) A randomized trial of beta carotene supplementation and cognitive function in men: the Physicians' Health Study II. Arch Intern Med 167, 2184-2190.
79. Teng EL, Chui HC (1987) The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 48, 314-318.
80. Kawas C, Segal J, Stewart WF, Corrada M, Thal LJ (1994) A validation study of the Dementia Questionnaire. Arch Neurol 51, 901-906.
81. Fitzpatrick AL, Fried LP, Williamson J, Crowley P, Posey D, Kwong L, Bonk J, Moyer R, Chabot J, Kidoguchi L, Furberg CD, DeKosky ST (2006) Recruitment of the elderly into a pharmacologic prevention trial: The Ginkgo Evaluation of Memory Study experience. Contemporary Clinical Trials 27, 541-553.
82. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
83. American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders, 3rd ed, revised, American Psychiatric Association, Washington DC.
84. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th ed., American Psychiatric Association, Washington DC.
85. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
86. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, et al. (1993) Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43, 250-260.
87. Reitan R (1958) Validity of the Trail Making Test as an indicator of brain damage. Perceptual and Motor Skills 8, 271-276.
88. Isaacs B, Kennie AT (1973) The Set test as an aid to the detection of dementia in old people. Br J Psychiatry 123, 467-470.
89. Goodglass H, Weintraub S (1983) The Boston Naming Test, Lea & Febiger, Philadelphia.
90. Grober E, Buschke H, Crystal H, Bang S, Dresner R (1988) Screening for dementia by memory testing. Neurology 38, 900-903.
91. Wechsler D (1981) WAIS-R Manual Psychological Corporation, New York.
92. Brandr J (1991) The Hopkins Verbal Learning Test: development of a new verbal memory test with six equivalent forms. Clin Neuropsychol 5, 125-142.
93. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C (1989) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39, 1159-1165.
94. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW (1963) Studies of Illness in the Aged. The Index of ADL: a Standardized Measure of Biological and Psychosocial Function. JAMA 185, 914-919.
95. Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9, 179-186.
96. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO (1982) Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 17, 37-49.
97. Radloff L (1977) The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1, 385-401.
98. Stroop J (1935) Studies of interference in serial verbal reactions. J Exp Psychol 19, 209-224.
99. Visser R (1985) Manual of the Complex Figure Test, Swets & Zeitlinger, Lisse, Netherlands.
100. Saan R, Deelman B (1986) De nieuwe 15-woordentest (A en B) een handleiding (New 15-words test (A and B) a manual), Swets & Zeitlinger, Lisse, Netherlands.
101. Wechsler D (1997) Wechsler Adult Intelligence Scale, The Psychological Corporation, Harcourt Brace, San Antonia, TX.
102. Scherr PA, Albert MS, Funkenstein HH, Cook NR, Hennekens CH, Branch LG, White LR, Taylor JO, Evans DA (1988) Correlates of cognitive function in an elderly community population. Am J Epidemiol 128, 1084-1101.
103. Wechsler D (1997) Wechsler Memory Scale: manual, Psychological Corporation, San Antonia, TX.
104. Wechsler D (1974) Wechsler Memory Scale, Psychological Corporation, New York.
105. Wilson B, Cockburn J, Baddeley A, Hiorns R (1989) The development and validation of a test battery for detecting and monitoring everyday memory problems. J Clin Exp Neuropsychol 11, 855-870.
106. McNair P, Lorr M, LF D (1971) Profile of Mood States Manual, Educational and Industrial Testing Service, San Diego, CA.
107. WHO (1993) The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research, World Health Organization, Geneva.
108. Van der Elst W, van Boxtel MP, van Breukelen GJ, Jolles J (2005) Rey's verbal learning test: normative data for 1855 healthy participants aged 24-81 years and the influence of age, sex, education, and mode of presentation. J Int Neuropsychol Soc 11, 290-302.
109. Albert M (1988) Geriatric Neuropsychology, Guildford Press, New York.
110. Kroenke K, Spitzer RL, Williams JB (2001) The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 16, 606-613.
111. Brandt J, Spencer M, Folstein M (1988) The telephone interview for cognitive status. Neuropsychiatry Neuropsychol Behav Neurol 1, 111-117.
112. Prince M, Macdonald A, Sham P, Richards M, Quraishi S, Horn I (1999) The development and initial validation of a telephone-administered cognitive test battery (TACT). Int J Meth Psychiatric Res 8, 49-57.
113. Green RC, DeKosky ST (2006) Primary prevention trials in Alzheimer disease. Neurology 67, S2-5.
114. Fabrigoule C, Rouch I, Taberly A, Letenneur L, Commenges D, Mazaux JM, Orgogozo JM, Dartigues JF (1998) Cognitive process in preclinical phase of dementia. Brain 121 (Pt 1), 135-141.
115. Larrieu S, Letenneur L, Orgogozo JM, Fabrigoule C, Amieva H, Le Carret N, Barberger-Gateau P, Dartigues JF (2002) Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology 59, 1594-1599.
116. Amieva H, Jacqmin-Gadda H, Orgogozo JM, Le Carret N, Helmer C, Letenneur L, Barberger-Gateau P, Fabrigoule C, Dartigues JF (2005) The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain 128, 1093-1101.
117. Boyle PA, Wilson RS, Aggarwal NT, Tang Y, Bennett DA (2006) Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline. Neurology 67, 441-445.
118. Tuokko H, Frerichs R, Graham J, Rockwood K, Kristjansson B, Fisk J, Bergman H, Kozma A, McDowell I (2003) Five-year follow-up of cognitive impairment with no dementia. Arch Neurol 60, 577-582.
119. Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G (2008) Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurol 7, 436-450.
120. Barberger-Gateau P, Fabrigoule C, Helmer C, Rouch I, Dartigues JF (1999) Functional impairment in instrumental activities of daily living: an early clinical sign of dementia? J Am Geriatr Soc 47, 456-462.
121. Peres K, Chrysostome V, Fabrigoule C, Orgogozo JM, Dartigues JF, Barberger-Gateau P (2006) Restriction in complex activities of daily living in MCI: impact on outcome. Neurology 67, 461-466.
122. Koss E, Patterson MB, Ownby R, Stuckey JC, Whitehouse PJ (1993) Memory evaluation in Alzheimer's disease. Caregivers' appraisals and objective testing. Arch Neurol 50, 92-97.
123. McGlone J, Gupta S, Humphrey D, Oppenheimer S, Mirsen T, Evans DR (1990) Screening for early dementia using memory complaints from patients and relatives. Arch Neurol 47, 1189-1193.
124. Ready RE, Ott BR, Grace J (2004) Validity of informant reports about AD and MCI patients' memory. Alzheimer Dis Assoc Disord 18, 11-16.
125. Flicker C, Ferris SH, Reisberg B (1993) A longitudinal study of cognitive function in elderly persons with subjective memory complaints. J Am Geriatr Soc 41, 1029-1032.
126. Jorm AF, Christensen H, Korten AE, Henderson AS, Jacomb PA, Mackinnon A (1997) Do cognitive complaints either predict future cognitive decline or reflect past cognitive decline? A longitudinal study of an elderly community sample. Psychol Med 27, 91-98.
127. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's disease. Am J Psychiatry 141, 1356-1364.
128. Morris JC, Weintraub S, Chui HC, Cummings J, Decarli C, Ferris S, Foster NL, Galasko D, Graff-Radford N, Peskind ER, Beekly D, Ramos EM, Kukull WA (2006) The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 20, 210-216.
129. Harrison J, Minassian S, Jenkins L, Black R, Koller M, Grundman M (2007) A Neuropsychological Test Battery for use in Alzheimer's Disease trials. Arch Neurol64, 1323-1329.
130. Harrison JE (2007) Measuring cognitive change in Alzheimer's disease clinical drug trials. J Nutr Health Aging 11, 327-329.
131. Visser PJ (2006) Role of cognitive testing in disease modifying AD trials. J Nutr Health Aging 10, 131-132; discussion 132-133.
132. Brandt J, Folstein M (2003) Telephone Interview for cognitive Status: Professional Manual, Psychological Assessment Resources Inc, Lutz, Fla.
133. Ferris SH, Aisen PS, Cummings J, Galasko D, Salmon DP, Schneider L, Sano M, Whitehouse PJ, Edland S, Thal AL (2006) ADCS Prevention Instrument Project: Overview and Initial Results. Alzheimer Dis Assoc Disord 20 Suppl 3, S109-S123.
134. Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, Cheng R, Hasegawa H, Chen F, Shibata N, Lunetta KL, Pardossi-Piquard R, Bohm C, Wakutani Y, Cupples LA, Cuenco KT, Green RC, Pinessi L, Rainero I, Sorbi S, Bruni A, Duara R, Friedland RP, Inzelberg R, Hampe W, Bujo H, Song YQ, Andersen OM, Willnow TE, Graff-Radford N, Petersen RC, Dickson D, Der SD, Fraser PE, Schmitt-Ulms G, Younkin S, Mayeux R, Farrer LA, St George-Hyslop P (2007) The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 39, 168-177.
135. Gao S, Hendrie HC, Hall KS, Hui S (1998) The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. Arch Gen Psychiatry 55, 809-815.
136. Kawas C, Gray S, Brookmeyer R, Fozard J, Zonderman A (2000) Age-specific incidence rates of Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 54, 2072-2077.
137. Rocca WA, Cha RH, Waring SC, Kokmen E (1998) Incidence of dementia and Alzheimer's disease: a reanalysis of data from Rochester, Minnesota, 1975-1984. Am J Epidemiol 148, 51-62.
138. Norton MC, Breitner JC, Welsh KA, Wyse BW (1994) Characteristics of nonresponders in a community survey of the elderly. J Am Geriatr Soc 42, 1252-1256.
139. Thal LJ (2006) Prevention of Alzheimer disease. Alzheimer Dis Assoc Disord 20, S97-99.
140. Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Green RC (2005) Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study. J Geriatr Psychiatry Neurol 18, 250-255.
141. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC, Palumbo PJ (1997) Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 145, 301-308.
142. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R (2001) Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 154, 635-641.
143. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM (1999) Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53, 1937-1942.
144. Peila R, Rodriguez BL, Launer LJ (2002) Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51, 1256-1262.
145. Gabryelewicz T, Pawlowska-Detko A, Misko J, Cwikla JB, Pfeffer A, Barczak A, Wasiak B, Luczywek E, Krolicki L, Walecki J, Barcikowska M(2007) Prediction of deterioration of mild cognitive impairment with CT and SPECT. Med Sci Monit 13 Suppl 1, 31-37.
146. Geroldi C, Rossi R, Calvagna C, Testa C, Bresciani L, Binetti G, Zanetti O, Frisoni GB (2006) Medial temporal atrophy but not memory deficit predicts progression to dementia in patients with mild cognitive impairment. J Neurol Neurosurg Psychiatry 77, 1219-1222.
147. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG (2007) Association of low plasma
148. Hansson O, Buchhave P, Zetterberg H, Blennow K, Minthon L, Warkentin S (2009) Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease. Neurobiol Aging 30, 165-173.
149. Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, Blennow K (2007) Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 23, 316-320.
150. Ellis PM, Butow PN, Tattersall MH, Dunn SM, Houssami N (2001) Randomized clinical trials in oncology: understanding and attitudes predict willingness to participate. J Clin Oncol 19, 3554-3561.
151. Halpern SD, Karlawish JH, Casarett D, Berlin JA, Townsend RR, Asch DA (2003) Hypertensive patients' willingness to participate in placebo-controlled trials: implications for recruitment efficiency. Am Heart J 146, 985-992.
152. Reed DM, MacLean CJ, Hayashi T (1987) Predictors of atherosclerosis in the Honolulu Heart Program. I. Biologic, dietary, and lifestyle characteristics. Am J Epidemiol 126, 214-225.
153. Cummings JH, Bingham SA (1998) Diet and the prevention of cancer. BMJ 317, 1636-1640.
154. Gardette V, Coley N, Toulza O, Andrieu S (2007) Attrition in geriatric research: how important is it and how should it be dealt with? J Nutr Health Aging 11, 265-271.
155. Di Bari M, Pahor M, Franse LV, Shorr RI, Wan JY, Ferrucci L, Somes GW, Applegate WB (2001) Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in the elderly program (SHEP) trial. Am J Epidemiol 153, 72-78.
156. DeKosky ST (2006) Maintaining adherence and retention in dementia prevention trials. Neurology 67, S14-16.
157. Chatfield MD, Brayne CE, Matthews FE (2005) Asystematic literature review of attrition between waves in longitudinal studies in the elderly shows a consistent pattern of dropout between differing studies. J Clin Epidemiol 58, 13-19.
158. Jacova C, Hsiung GY, Feldman HH (2006) Dropouts and refusals in observational studies: Lessons for prevention trials. Neurology 67, S17-20.
159. Commenges D, Letenneur L, Joly P, Alioum A, Dartigues JF (1998) Modelling age-specific risk: application to dementia. Stat Med 17, 1973-1988.
160. Saczynski JS, Pfeifer LA, Masaki K, Korf ES, Laurin D, White L, Launer LJ (2006) The effect of social engagement on incident dementia: the Honolulu-Asia Aging Study. Am J Epidemiol 163, 433-440.
161. Fratiglioni L, Paillard-Borg S, Winblad B (2004) An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol 3, 343-353.
162. Whalley LJ, Dick FD, McNeill G (2006) A life-course approach to the aetiology of late-onset dementias. Lancet Neurol 5, 87-96.
163. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A (2001) Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 322, 1447-1451.
164. Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W, Nelson J, Davis DG, Hardman J, Foley DJ, Launer LJ (2000) Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging Study. Neurobiol Aging 21, 57-62.
165. Wellman NS, Kamp B, Kirk-Sanchez NJ, Johnson PM (2007) Eat better & move more: a community-based program designed to improve diets and increase physical activity among older Americans. Am J Public Health 97, 710-717.
166. WHO (2001) Men Ageing and Health. Achieving health across the life span. http://whqlibdoc.who.int/hq/2001/WHO-NMH-NPH-01.2.pdf.